Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases
Talawar Therapeutics is set to become a publicly traded company following a definitive business combination agreement with JATT II Acquisition Corp.
📍 How it ended
The SPAC deal between Talawar Therapeutics and JATT II Acquisition Corp. was finalized, merging the biotech company into a publicly listed entity on Nasdaq. The agreement positioned Talawar as a subsidiary focused on developing bispecific treatments for inflammatory and immune-related diseases, including eczema.
Coverage of the transaction ended without further updates on its market performance or clinical progress.
Epilogue added 44d ago, after coverage quieted.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Talawar Therapeutics has entered into a merger agreement with JATT II Acquisition Corp. Under the terms of the deal, JATT II Acquisition Corp. will become a subsidiary of the biotechnology company.
This transaction is designed to facilitate the transition to a Nasdaq listing. Coverage from PR Newswire, TradingView, Endpoints News, statnews.com, and Fierce Biotech emphasizes the company’s focus on developing bispecific therapies for immunology and inflammation (I&I) diseases.
Future developments will depend on the completion of the business combination process. Coverage does not yet specify the timeline for the final public listing or the clinical milestones that will follow the funding.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (86% supported) Updated 45d ago.
Coverage (5)
- JATT II Acquisition to Merge With Talawar Tx; JATT to Become Subsidiary in SPAC Deal TradingView · 47d ago
- Biotech SPAC deal gets it to Nasdaq; AstraZeneca Phase 3 win in children's bone disease Endpoints News · 47d ago
- Talawar bets bispecific approach can shake up eczema market statnews.com · 47d ago
- 'There's room for multiple winners': Talawar heads to Nasdaq via SPAC deal to bankroll eczema asset Fierce Biotech · 47d ago
- Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases PR Newswire · 47d ago
Quick answers
What is the primary goal of the merger?
The merger aims to create a publicly listed biotechnology company and provide funding for Talawar Therapeutics' eczema asset.
How will the corporate structure change?
JATT II Acquisition Corp. will become a subsidiary of Talawar Therapeutics.
What medical field does Talawar Therapeutics focus on?
The company focuses on developing bispecifics for immunology and inflammation diseases, including eczema.
Topics
From around our network
- The Money Market Podcast: Insights for Business Leaders and Entrepreneurs world-today-news.com
Related trends
Stock Market Today: Microsoft Stock Rallies; Jersey Mike's IPO in Focus
Investors are seeing significant shifts in market momentum as major tech firms drive a broad rally in U.S. stock indices.
Stock Market Today: Nasdaq Leaps at Open; Treasury Yields at Multiyear Highs
Financial markets are experiencing volatility as Meta’s financial outlook and Federal Reserve interest rate decisions trigger a widespread sell-off in bonds.
Stock futures rise as Microsoft jumps after earnings; traders hope to recover from Fed Day sell-off: Live updates
Markets show divergence as Microsoft gains bolster tech stocks while Meta earnings trigger a decline and bond market inflation concerns persist.
As Elon Musk Promises The Future, Tesla Stock Slides Into The Past
Tesla’s shares tumble, wiping out a year’s gains as Elon Musk’s future promises meet analyst doubt.
MapLight shares sink on mixed ph. 2 schizophrenia readout
MapLight Therapeutics stock plummeted 73% following mixed phase 2 trial data for its schizophrenia candidate, ML-007C-MA.
FDA staff flags data concerns about Capricor's therapy; shares plunge
Capricor Therapeutics faces market volatility and legal investigations following the release of FDA staff documents regarding its therapy, Deramiocel.